Diagnostic and Prognostic Biomarkers in Parkinson Disease

Study Overview
=================
Brief Summary
-----------------
The overall goal of PROBE is to evaluate the feasibility and potential utility of three markers (alpha-synuclein, transcriptomic profiles and olfactory function) to determine the risk or prognosis of PD.

Detailed Description
-----------------
PROBE will test three biomarkers in PD subjects and controls to determine their feasibility and potential utility as markers of risk and prognosis for PD. This is a case control study, in which PD subjects will be compared to neurologically healthy controls and disease controls (MSA and PSP). The blood biomarker samples will be drawn once to evaluate blood alpha-synuclein levels as well as collection of lymphocyte mass for array analysis. Olfaction will be measured using the UPSIT for all subjects. The UPSIT will be conducted as part of PostCEPT for PD subjects and will only be repeated in this study for PD subjects in not done within 6 months. Control subjects may also choose to submit a blood specimen for processing and storage at the Coriell Institute for Medical Research, a research resource supported by the NINDS Human Genetics Resource Center. Follow-up of the PD population over a 3-year period will allow us to evaluate the prognosis for important motor aspects of PD that will occur frequently in this cohort. These complications of PD include motor complications, postural instability, and non-motor impairment such as cognitive decline. Healthy and disease control subjects may give permission at the Baseline visit to be contacted and followed in the previously established PSG FOUND study using mail and telephone contact to assess clinical status. Participation in the FOUND study provides another mechanism to maintain contact with subjects and collect supplemental data beyond that collected at the PROBE Baseline visit.

Official Title
-----------------
Blood Alpha-Synuclein, Gene Expression, and Smell Testing as Diagnostic and Prognostic Biomarkers in Parkinson's Disease

Conditions
-----------------
Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy

Participation Criteria
=================
Eligibility Criteria
-----------------
Parkinson Disease Inclusion Criteria: Subject is participating in PostCEPT and meets UK brain bank criteria for PD Willing and able to provide informed consent Healthy Control Inclusion Criteria: Spouse or non blood relative of the PD subject No known current diagnosis or history of a neurological disease MMSE score >27 Age >45 Willing and able to provide informed consent Parkinsonism/Disease Control Inclusion Criteria (MSA and PSP) A diagnosis of Probable MSA based on Consensus Criteria OR Probable PSP based on NINDS-PSP Criteria Willing and able to provide informed consent Exclusion Criteria for All Groups: Current use (within 7 days prior to Baseline Visit) of anticoagulants (e.g., warfarin or heparin) Known bleeding disorder (acquired or inherited) Known blood disorder (e.g. leukemia) or a history of anemia with a documented hematocrit <30 Known pregnancy History of nasal trauma, sinusitis, or other nasal pathology that would interfere with smell testing

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| α-synuclein, transcriptomic profiles and olfactory function |  | Three years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Unified Parkinson Disease Rating Scale (UPDRS) |  | Three Years | 
| University of Pennsylvania Smell Identification Test (UPSIT) |  | Three Years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Parkinson disease, Multiple System Atrophy, MSA, Progressive Supranuclear Palsy, PSP, observational, biomarker